March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Conjunctival Papilloma features and outcomes in 70 consecutive patients
Author Affiliations & Notes
  • Kendra A. Klein
    University of Rochester, Rochester, New York
  • Swathi Kaliki
    Ocular Oncology,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • Eralda Hysenj
    Ophthalmology, S Paolo Hospital Milan, Milan, Italy
  • Carol L. Shields
    Oncology Service,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  Kendra A. Klein, None; Swathi Kaliki, None; Eralda Hysenj, None; Carol L. Shields, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3988. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kendra A. Klein, Swathi Kaliki, Eralda Hysenj, Carol L. Shields; Conjunctival Papilloma features and outcomes in 70 consecutive patients. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3988.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To describe clinical features and outcomes of treatment of conjunctival papilloma.

Methods: : Retrospective chart review of 70 patients with 91 tumors.

Results: : The mean age at presentation of conjunctival papilloma was 47 years, with 14 tumors (15%) in children (≤20 years) and 77 tumors (85%) in adults (>20 years). The most common presenting symptom included mass (n=26; 37%) or a red spot (n=15; 21%). The tumor was located on the bulbar conjunctiva (n=23; 25%), caruncle (n=18; 20%), the forniceal conjunctiva (n=15; 17%), tarsal conjunctiva (n=14; 15%), plica semilunaris (n=13; 14%), lid margin (n=4; 4%), limbus (n=3; 3%), and punctum (n=1; 1%). The mean tumor basal diameter was 8 mm (millimeters) (median, 6 mm; range, 1 to 35 mm), and mean tumor thickness was 3 mm (median, 3 mm; range, 0.5 to 10 mm). The tumors were treated by surgical excision using the "no touch technique" and cryotherapy (n=59; 65%), plus supplemental oral cimetidine (n=8; 9%), or plus supplemental interferon (n=5; 6%). Sole treatment was given with oral cimetidine alone (n=6; 7%), topical interferon alone (n=4; 4%), photodynamic therapy alone (n=1; 1%), or cryotherapy alone (n=1; 1%). Cautious observation was employed in 3% (n=3), and 4% (n=4) were lost to follow-up. Associated conjunctival intraepithelial neoplasia was present in 8% (n=7), and invasive squamous cell carcinoma in 5% (n=5) cases. Recurrence of papilloma was noted in 5% (n=5) cases over a mean follow-up period of 50 months (median, 14; range 1 to 629 months). Of the five with recurrence, four achieved complete tumor regression (n=4; 80%) by further surgical excision and cryotherapy with supplemental oral cimetidine (n=2; 50%), supplemental interferon alpha-2b injection (n=1; 25%), or oral cimetidine alone (n=1; 25%).

Conclusions: : Conjunctival papilloma presents on the bulbar conjunctiva (25%), caruncle (20%), or fornix (17%) in both children and adults. Surgical excision plus cryotherapy plus supplemental oral cimetidine or interferon alpha-2b therapy ultimately control 99% of cases.

Keywords: conjunctiva • clinical (human) or epidemiologic studies: outcomes/complications • tumors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×